title: The changing pattern of management for hormone-refractory, metastatic prostate cancer.
abstract: Prostate cancer responds initially to hormonal manipulation by androgen withdrawal and peripheral androgen blockade. The inevitable progression to a hormone-refractory state is accompanied by an exacerbation of local symptoms and metastatic spread, principally to the bones, which has a considerable impact on quality of life and survival. Treatment of hormone-refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases. Systemic treatments are not widely accepted in this setting, but clinical trials have demonstrated the potential for bone targeting agents such as strontium-89 and the bisphosphonates to palliate painful bone metastases and to delay progression in certain settings. Chemotherapy with mitozantrone in combination with steroids has previously been shown to have palliative benefits and to delay progression. The additional costs incurred by the use of chemotherapy or bone-targeting therapies may be offset by gains in overall care with fewer in-patient admissions compared with steroid monotherapy. Recent clinical trials have demonstrated that docetaxel significantly improves patient quality of life, and importantly, increases survival. Future studies investigating the timing of chemotherapy, combinations with existing treatments or other novel therapies are underway.
authors.affiliation: Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK. n.d.james@bham.ac.uk
authors.forename: N D
authors.initials: ND
authors.lastname: James
authors.forename: D
authors.initials: D
authors.lastname: Bloomfield
authors.forename: C
authors.initials: C
authors.lastname: Luscombe
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D004164:Diphosphonates / Q000627:therapeutic use; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D009362:Neoplasm Metastasis / Q000628:therapy; D010166:Palliative Care / Q000379:methods; D011239:Prednisolone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000628:therapy*; D013117:Spinal Cord Compression / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D043823:Taxoids / Q000627:therapeutic use; D014570:Urologic Diseases / Q000209:etiology / Q000601:surgery
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D043823:Taxoids; D000077143:Docetaxel; D011239:Prednisolone; D008942:Mitoxantrone